Format

Send to

Choose Destination
Chin J Integr Med. 2017 Feb;23(2):105-109. doi: 10.1007/s11655-016-2503-4. Epub 2016 Aug 2.

Clinical observation of Shuanghuang Shengbai Granule () on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients.

Author information

1
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
2
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. xuzhenye1947@126.com.
3
Department of Integrated Medicine, Shanghai Chest Hospital, Shanghai, 200030, China.
4
Department of Oncology, Shanghai Punan Hospital of Pudong New District, Shanghai, 200125, China.
5
Department of Oncology, Shanghai Seventh People's Hospital, Shanghai, 310000, China.

Abstract

OBJECTIVE:

To study the efficacy and safety of Shuanghuang Shengbai Granule (, SSG), a traditional Chinese herbal medicine, on myelosuppression of cancer patients caused by chemotherapy.

METHODS:

A total of 330 patients were randomly assigned to the treatment group (220 cases, analysed 209 cases) and the control group (110 cases, analysed 102 cases) with a 2:1 ratio by envelope method. The patients in the treatment group at the first day of chemotherapy started to take SSG for 14 days, while the patients in the control group took Leucogon Tablets. The changes of the blood routine, clinical symptoms and immune function in both groups were observed for safety and efficacy evaluation.

RESULTS:

At the 7th day of chemotherapy, the white blood cells (WBCs) level in the treatment group was significantly higher than that in the control group (P<0.05). After treatment, the WBCs rate in the normal range accounted for 50.2% in the treatment group, the myelosuppression of WBCs and neutrophil were mainly grade I, while 8.1% and 5.7% of patients emerged grade III and grade IV myelosuppression, respectively. The incidence of myelosuppression of the treatment group was significantly lower than that of the control group (P<0.05). The total effective rate of Chinese medicine syndrome in the treatment group was significantly higher than that in the control group (84.2% vs. 72.5%, P<0.05). The immune cell levels in both groups were maintained in the normal range. Compared with that before treatment, the levels of CD3+ and CD4+ cells were significantly increased in the treatment group after treatment (P<0.05). The discrepancy of CD3+ and CD4+ cell activity before and after treatment in both groups were significantly different (P<0.05). No obvious adverse event occurred in both groups.

CONCLUSION:

SSG had a protection effect on bone marrow suppression, and alleviated the clinical symptoms together with clinical safety.

KEYWORDS:

Chinese medicine; Shuanghuang Shengbai Granule; chemotherapy; malignant tumor; myelosuppression

PMID:
27484763
DOI:
10.1007/s11655-016-2503-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center